Lightning Round OT: Immunogen, Synchronoss Tech and More

Immunogen : “I think it’s going to have a big year,” Cramer said of IMGN. He likes it as a speculative play on biotech.

Synchronoss Technologies : “It just had a very big move,” Cramer said, so investors should take profits.

Hi Tech Pharmacal : Cramer is bullish on HITK, he said, even at these price levels.

















Call Cramer: 1-800-743-CNBC

Questions for Cramer? madmoney@cnbc.com

Questions, comments, suggestions for the Mad Money website? madcap@cnbc.com